Dr. Sébastien Fortin PhD is a regular researcher at the Centre de recherche du CHU de Québec-Laval University, Director of a pharmaceutical chemistry laboratory located at the Hôpital Saint-François d’Assise, and Associate Professor at Laval University’s School of Pharmacy. He is author and co-author of 28 publications and co-inventor of 3 patents on the technologies that he develops. Dr. Fortin is the recipient of several awards and honors, including the Jean-François St-Denis Fellowship in Cancer Research from the Canadian Institutes of Health Research (CIHR) and the 2011 award for the best doctorate in cotutelle awarded by the Ministère des Relations internationales and the Consulat général de France à Québec. His research focuses on the design and development of new anticancer agents for use in personalized medicine.
Development of new drugs for personalized cancer chemotherapy
In Canada, cancer is the leading cause of death, followed only by cardiovascular diseases. Cancer is therefore a major public health problem. Despite recent medical breakthroughs, the ability to cure all cancer patients remains elusive. Consequently, we need to develop new treatments that will be more efficient, and more selective against cancer tumors, with the aim of improving the life expectancy and the quality of life of cancer patients. The aim of my research program is to design and prepare new anticancer agents exhibiting optimal biopharmaceutical and anticancer properties suitable for preclinical and clinical studies. My research themes are divided in two parts: 1) development of new inhibitors of DNA repair and replication mechanisms and 2) development of new inhibitors targeting cells deficient in homologous recombination. My research programs involve and focus on several interrelated and complementary disciplines, including molecular design and modeling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to the development of new, efficient and personalized anticancer treatments.
10, rue de l'Espinay
Canada G1L 3L5
- Bouzriba, ChahrazedDoctoral email@example.com
- Bruxelles, QuentinDoctoral studentCHUL+1 418-525-4444, extension firstname.lastname@example.org
2705, boulevard Laurier
Canada G1V 4G2
- Chavez Alvarez, Atziri CorinDoctoral email@example.com@crchudequebec.ulaval.ca
- Hamel-Côté, GenevièveEmployeegenevieve.firstname.lastname@example.org
- Ouellette, VincentDoctoral student+1 418-525-4444, extension email@example.com
- Ringuette, JoanieMaster studentHôpital Saint-François d'Assise+1 418-525-4444, extension firstname.lastname@example.org
10, rue de l'Espinay
Canada G1L 3L5
- Scavo, LindaPostdoctoral email@example.com
Stereoselective Synthesis of Fluorinated Galactopyranosides as Potential Molecular Probes for Galactophilic Proteins: Assessment of Monofluorogalactoside-LecA InteractionsJournal Article
Chemistry, 25 (17), 2019.
Diversity-Oriented Synthesis of Diol-Based Peptidomimetics as Potential HIV Protease Inhibitors and Antitumor AgentsJournal Article
Preparation, characterisation and biological evaluation of new N-phenyl amidobenzenesulfonates and N-phenyl ureidobenzenesulfonates inducing DNA double-strand breaks. Part 3. Modulation of ring AJournal Article
Eur J Med Chem, 155 , 2018.
4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cellsJournal Article
Bioorg Med Chem, 26 (18), 2018.
Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer CellsJournal Article
J Med Chem, 60 (12), 2017.
Investigation of the DNA damage response to SFOM-0046, a new small-molecule drug inducing DNA double-strand breaksJournal Article
Sci Rep, 6 , 2016.
New testosterone derivatives as semi-synthetic anticancer agents against prostate cancer: synthesis and preliminary biological evaluationJournal Article
Med Chem, 11 (6), 2015.
Synthesis and biological evaluation of novel N-phenyl ureidobenzenesulfonate derivatives as potential anticancer agents. Part 2. Modulation of the ring BJournal Article
Eur J Med Chem, 103 , 2015.
Styryl-N-phenyl-N'-(2-chloroethyl)ureas and styrylphenylimidazolidin-2-ones as new potent microtubule-disrupting agents using combretastatin A-4 as modelJournal Article
Eur J Med Chem, 100 , 2015.
Novel Cytocidal Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl) Benzenesulfonates and Benzenesulfonamides with Affinity to the Colchicine-Binding Site: Is the Phenyl 2-Imidazolidinone Moiety a New Haptophore for the Design of New Antimitotics?Journal Article
Open J Med Chem, 5 , 2014.
- Computational design, synthesis, and screening of FUT8 inhibitors as new anticancer agents_Fortin, from 2022-09-01 to 2023-08-31
- Design and synthesis of FUT8 inhibitors as new anticancer agents - Fortin, from 2022-04-01 to 2023-07-31
- Eleclazine: “Boosting” efficacy and safety of the antineoplastic drug Alpelisib (Piqray®)?, from 2023-01-01 to 2024-12-30
- Les phénylureidobenzènesulfonates, une nouvelle thérapie de différenciation pour le traitement de la leucémie myéloïde aiguë : preuve de concept, from 2020-02-01 to 2024-01-31
- L’AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1, from 2021-10-01 to 2026-09-30
- Pharmacological optimization of OpKemo, a silica-based nanoparticle platform for oncology, from 2022-01-31 to 2024-03-31
- Projet parent « Design and synthesis of FUT8 inhibitors as new anticancer agents, from 2022-04-01 to 2023-07-31
Recently finished projects
- Appui financier du Fonds de recherche de l’Hôpital Saint-François d'Assise pour le support de doctorants.es au laboratoire du Dr Sébastien Fortin, from 2020-05-01 to 2022-04-30
- Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site, from 2016-04-01 to 2023-03-31
- Conception de nouveaux agents anticancéreux ciblant les mécanismes, from 2018-07-01 to 2022-06-30
- Conception de nouveaux agents anticancéreux ciblant les mécanismes de réparation et de réplication de l'ADN en vue de leur utilisation en médecine personnalisée, from 2018-07-01 to 2022-06-30